| Semaglutide and cardiovascular outcomes in patients with type 2 diabetes SP Marso, SC Bain, A Consoli, FG Eliaschewitz, E Jódar, LA Leiter, ... New England Journal of Medicine 375 (19), 1834-1844, 2016 | 5219 | 2016 |
| Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 121-130, 2019 | 2254 | 2019 |
| Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes M Husain, AL Birkenfeld, M Donsmark, K Dungan, FG Eliaschewitz, ... New England Journal of Medicine 381 (9), 841-851, 2019 | 1375 | 2019 |
| Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial AF Hernandez, JB Green, S Janmohamed, RB D'Agostino, CB Granger, ... The Lancet 392 (10157), 1519-1529, 2018 | 1334 | 2018 |
| Physiology and role of irisin in glucose homeostasis N Perakakis, GA Triantafyllou, JM Fernández-Real, JY Huh, KH Park, ... Nature reviews endocrinology 13 (6), 324-337, 2017 | 584 | 2017 |
| Leptin suppression of insulin secretion and gene expression in human pancreatic islets: implications for the development of adipogenic diabetes mellitus J Seufert, TJ Kieffer, CA Leech, GG Holz, W Moritz, C Ricordi, JF Habener The Journal of clinical endocrinology & metabolism 84 (2), 670-676, 1999 | 532 | 1999 |
| Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial HC Gerstein, HM Colhoun, GR Dagenais, R Diaz, M Lakshmanan, P Pais, ... The Lancet 394 (10193), 131-138, 2019 | 531 | 2019 |
| Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ... The Lancet 393 (10184), 1937-1947, 2019 | 493 | 2019 |
| Leptin effects on pancreatic β-cell gene expression and function J Seufert Diabetes 53 (suppl_1), S152-S158, 2004 | 451 | 2004 |
| Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn’s Registry E Born-Frontsberg, M Reincke, LC Rump, S Hahner, S Diederich, ... The Journal of Clinical Endocrinology & Metabolism 94 (4), 1125-1130, 2009 | 327 | 2009 |
| Leptin inhibits insulin gene transcription and reverses hyperinsulinemia in leptin-deficient ob/ob mice J Seufert, TJ Kieffer, JF Habener Proceedings of the National Academy of Sciences 96 (2), 674-679, 1999 | 314 | 1999 |
| Adrenal venous sampling: evaluation of the German Conn's registry O Vonend, N Ockenfels, X Gao, B Allolio, K Lang, K Mai, I Quack, A Saleh, ... Hypertension 57 (5), 990-995, 2011 | 283 | 2011 |
| Effects of high glucose on mesenchymal stem cell proliferation and differentiation YM Li, T Schilling, P Benisch, S Zeck, J Meissner-Weigl, D Schneider, ... Biochemical and biophysical research communications 363 (1), 209-215, 2007 | 273 | 2007 |
| Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial C Mathieu, P Dandona, P Gillard, P Senior, C Hasslacher, E Araki, M Lind, ... Diabetes care 41 (9), 1938-1946, 2018 | 253 | 2018 |
| Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY … KK Ray, HM Colhoun, M Szarek, M Baccara-Dinet, DL Bhatt, VA Bittner, ... The lancet Diabetes & endocrinology 7 (8), 618-628, 2019 | 248 | 2019 |
| Octreotide therapy for tumor-induced osteomalacia J Seufert, K Ebert, J Müller, J Eulert, C Hendrich, E Werner, N Schütze, ... New England Journal of Medicine 345 (26), 1883-1888, 2001 | 248 | 2001 |
| Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas D Wild, E Christ, ME Caplin, TR Kurzawinski, F Forrer, M Brändle, ... Journal of Nuclear Medicine 52 (7), 1073-1078, 2011 | 229 | 2011 |
| Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets JH DeVries, SC Bain, HW Rodbard, J Seufert, D D’Alessio, AB Thomsen, ... Diabetes care 35 (7), 1446-1454, 2012 | 221 | 2012 |
| Pharmacotherapy of type 2 diabetes: an update J Upadhyay, SA Polyzos, N Perakakis, B Thakkar, SA Paschou, N Katsiki, ... Metabolism 78, 13-42, 2018 | 212 | 2018 |
| Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo … DL Bhatt, PG Steg, SR Mehta, LA Leiter, T Simon, K Fox, C Held, ... The Lancet 394 (10204), 1169-1180, 2019 | 203 | 2019 |
